

Zimmer Biomet Receives FDA 510(k) Clearance for Hip Implant System for Challenging Primary and Revision Cases

G7® TM Acetabular System Features Trabecular Metal® Technology and Proprietary Screw Pattern with Perimeter Holes Designed to Support Stable Fixation in Compromised Bone

(WARSAW, Ind.) Feb. 5, 2026 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the G7 TM Acetabular System, a next-generation implant engineered to address challenging primary and revision hip replacement surgeries.

Built on Zimmer Biomet’s trusted G7 platform, the new system combines Trabecular Metal Technology with an anatomic screw-hole pattern, featuring Rim Fix™ Screws and perimeter holes designed to provide multiple points of access and engagement to help surgeons achieve stable fixation in compromised bone.

“FDA clearance of the G7 TM Acetabular System marks an important milestone for our hip portfolio and our commitment to advancing solutions for complex procedures,” said Lou Galrao, president of Reconstruction at Zimmer Biomet. “By integrating Trabecular Metal Technology with anatomic screw holes and Rim Fix Screws, we’re delivering a system designed to help surgeons address difficult cases while maintaining compatibility with the full G7 ecosystem.”

Designed for challenging primary and revision cases

- **Trabecular Metal Technology:** The G7 TM shell’s Trabecular Metal porous surface is made from elemental tantalum with structural, functional and physiological properties similar to bone. The material features a 100% open, engineered and interconnected pore structure to support biological fixation and vascularization with more than 20 years of documented clinical history in a wide variety of orthopedic applications.^{1,2,3,4,5}
- **Anatomically Derived Screw Hole Pattern:** The G7 TM shell incorporates strategically placed anatomic dome screw holes that directly align with patient anatomy to maximize shell fixation. The placement of the holes was guided by Zimmer Biomet’s custom anatomical modeling system, ZiBRA™, which uses a large database of 3D reconstructed bone scans, both male and female, representing a diverse global population.
- **Rim Fix Screws:** G7 TM shells incorporate perimeter screw holes located within 5 mm of the shell rim to facilitate Rim Fix screw placement in the ischium and superior ramus of the pubis. Preclinical testing demonstrated the addition of Rim

Fix screws, in conjunction with dome screws, reduced micromotion and aided in increased initial construct stability.⁶

- **G7 System Compatibility:** The system is compatible with multiple G7 liners — including Dual Mobility and Freedom® Constrained — offering the same proven versatility to establish a stable joint in total hip arthroplasty.

With FDA 510(k) clearance, Zimmer Biomet will initiate U.S. commercialization of the G7™ Acetabular System, supported by surgeon education and training programs, with full commercial launch expected by the end of the first quarter. The system is also compatible with Zimmer Biomet's broader revision portfolio, including solutions for complex acetabular and femoral reconstruction.

###

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future

events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

Contacts:

Media

Troy Kirkpatrick

614-284-1926

troy.kirkpatrick@zimmerbiomet.com

Kirsten Fallon

781-779-5561

kirsten.fallon@zimmerbiomet.com

Investors

David DeMartino

646-531-6115

david.demartino@zimmerbiomet.com

Zach Weiner

908-591-6955

zach.weiner@zimmerbiomet.com

¹ Bobynd JD. et al. Characterization of new porous tantalum biomaterial for reconstructive orthopaedics. AAOS 66th Annual Meeting; 1999; Anaheim, CA.

² Karageorgiou V, Kaplan D. Porosity of biomaterial scaffolds and osteogenesis. *Biomaterials*. 2005;26:5474–5491.

³ Bobynd JD. et al. Characterization of new porous tantalum biomaterial for reconstructive orthopaedics. AAOS 66th Annual Meeting; 1999; Anaheim, CA.

⁴ Karageorgiou V, Kaplan D. Porosity of biomaterial scaffolds and osteogenesis. *Biomaterials*. 2005;26:5474–5491.

⁵ Zhang Y. et al. Interfacial frictional behavior of bone and porous tantalum. *J Musculoskelet Res*. 1999.

⁶ G7 Revision Micromotion Verification (Zimmer Biomet, data on file, 2025).